Next-generation monoclonals less profitable than trailblazers?
Mitchell
Peter
P
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D004345:Drug Industry / Q000191:economics* / Q000639:trends*; D005060:Europe; D007167:Immunotherapy / Q000191:economics* / Q000639:trends*; D007182:Income / Q000639:trends*; D014481:United States
D000911:Antibodies, Monoclonal